secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2024-12-09T23:59:59+00:00
Accession:  0001193125-24-273406
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verrica appoints David Zawitz as COO effective Dec 9; grants 950,000 option shares
--------------------------------------------------------------------------------

- David Zawitz appointed Chief Operating Officer and principal operating officer, effective Dec 9, 2024.
- Base salary of $250,000/year; target annual bonus of 40% of base salary.
- Option grant for 950,000 shares at closing price on grant date, vesting over 4 years with accelerated vesting on change-in-control termination.
- 2024 Inducement Plan shares increased from 2,000,000 to 4,500,000 to accommodate the grant.
- Zawitz to continue consulting for PBM Capital with Board approval for increased time.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312524273406/0001193125-24-273406-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312524273406/d878105d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-273406

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer